Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Scientific Reports
|
February 20, 2013
ASBEL, an ANA/BTG3 antisense transcript required for tumorigenicity of ovarian carcinoma
Satoshi Yanagida, Kenzui Taniue, Hironobu Sugimasa, et al.
Journal of Robotic Surgery
|
February 15, 2026
Optimal tissue retrieval in robot-assisted total laparoscopic hysterectomy
Yoshihiko Matsuzaki, Hiroe Ito, Shiori Fukuda, et al.
Gynecologic Oncology
|
February 8, 2021
Re-thinking the prognostic significance of positive peritoneal cytology in endometrial cancer
Masataka Takenaka, Misato Kamii, Yasushi Iida, et al.
Plos One
|
June 9, 2017
Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation
Satoshi Yanagida, Michael S Anglesio, Tayyebeh M Nazeran, et al.
Gynecologic Oncology
|
November 20, 2022
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway
Nozomu Yanaihara, Yuki Yoshino, Daito Noguchi, et al.
Diagnostics (Basel, Switzerland)
|
July 12, 2025
Two Cases of Chronic Tubular Necrosis Presenting as Fanconi Syndrome Induced by Red Yeast Rice Choleste-Help
Kanako Mita, Shunsuke Takahashi, Satoshi Yanagida, et al.
Plos One
|
January 18, 2013
The cancer stem cell marker CD133 interacts with plakoglobin and controls desmoglein-2 protein levels
Ryo Koyama-Nasu, Rina Takahashi, Satoshi Yanagida, et al.
Journal of Gynecologic Oncology
|
November 7, 2025
Molecular and pathological analysis of <i>FOXL2</i> and <i>TERT</i> promoter mutations in adult-type granulosa cell tumors of the ovary: a study of 64 Japanese patients
Satoshi Yanagida, Yuichi Shoburu, Takako Kiyokawa, et al.
Scientific Reports
|
April 9, 2021
Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma
Toshiyuki Seki, Nozomu Yanaihara, Jason Solomon Shapiro, et al.
Anti-Cancer Drugs
|
February 2, 2023
Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601
Kimihiko Ito, Mio Nakagawa, Mototsugu Shimokawa, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Scientific Reports
|
February 20, 2013
ASBEL, an ANA/BTG3 antisense transcript required for tumorigenicity of ovarian carcinoma
Satoshi Yanagida, Kenzui Taniue, Hironobu Sugimasa, et al.
Journal of Robotic Surgery
|
February 15, 2026
Optimal tissue retrieval in robot-assisted total laparoscopic hysterectomy
Yoshihiko Matsuzaki, Hiroe Ito, Shiori Fukuda, et al.
Gynecologic Oncology
|
February 8, 2021
Re-thinking the prognostic significance of positive peritoneal cytology in endometrial cancer
Masataka Takenaka, Misato Kamii, Yasushi Iida, et al.
Plos One
|
June 9, 2017
Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation
Satoshi Yanagida, Michael S Anglesio, Tayyebeh M Nazeran, et al.
Gynecologic Oncology
|
November 20, 2022
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway
Nozomu Yanaihara, Yuki Yoshino, Daito Noguchi, et al.
Diagnostics (Basel, Switzerland)
|
July 12, 2025
Two Cases of Chronic Tubular Necrosis Presenting as Fanconi Syndrome Induced by Red Yeast Rice Choleste-Help
Kanako Mita, Shunsuke Takahashi, Satoshi Yanagida, et al.
Plos One
|
January 18, 2013
The cancer stem cell marker CD133 interacts with plakoglobin and controls desmoglein-2 protein levels
Ryo Koyama-Nasu, Rina Takahashi, Satoshi Yanagida, et al.
Journal of Gynecologic Oncology
|
November 7, 2025
Molecular and pathological analysis of <i>FOXL2</i> and <i>TERT</i> promoter mutations in adult-type granulosa cell tumors of the ovary: a study of 64 Japanese patients
Satoshi Yanagida, Yuichi Shoburu, Takako Kiyokawa, et al.
Scientific Reports
|
April 9, 2021
Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma
Toshiyuki Seki, Nozomu Yanaihara, Jason Solomon Shapiro, et al.
Anti-Cancer Drugs
|
February 2, 2023
Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601
Kimihiko Ito, Mio Nakagawa, Mototsugu Shimokawa, et al.
Page
of 3